Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Slides:

Advertisements

Similar presentations

Here are some CML slides that may be helpful for your presentation.

Advertisements

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

SIGNAL TRANSDUCTION Signal Transduction Pathway Protein Modification Phosphorylation Cascade Protein Kinases.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 1 Concept of the therapeutic index

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Ali A Khorasani Bethany Bennett Jenna Rozacky November 21, 2011

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Volume 100, Issue 1, Pages (January 2000)

Important port for SHIP-1 at Dok-3

Figure 1 Classical and non-classical models of the cell cycle in RB1-proficient cells Figure 1 | Classical and non-classical models of the cell cycle in.

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The multidomain structure of c-MET and its ligand, HGF

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Targeting kinases in CML CLL

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 2 HGF/c-MET signalling pathway

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Figure 1 Research advances in osteoarthritis management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Valerie D. Myers et al. BTS 2018;3:

Figure 2 Approaches to improve CAR-T-cell therapy

RASopathy Gene Mutations in Melanoma

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Switching on BTK—One Domain at a Time

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 2 Signalling downstream of the IL-6 receptor

Figure 4 Molecular signalling and immunological

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Mechanisms of RET activation in cancer

Ibrutinib Treatment of CLL: The Cancer Fights Back

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Inhibition of BCR-mediated signaling by ARQ 531.

Presentation transcript:

Figure 1 Therapeutic targeting of the B-cell receptor (BCR) signalling pathway in patients with lymphoma Figure 1 | Therapeutic targeting of the B-cell receptor (BCR) signalling pathway in patients with lymphoma. a | BCR signalling pathway. Selective inhibitors for Syk and Btk are either approved by regulatory agencies or are in clinical trials. b | SYK structure. SYK is a non-receptor protein-tyrosine kinase containing tandem SRC homology 2 (SH2) domains. SYK inhibitors are able to competitively bind to the ATP-binding pocket of the kinase domain. Most BTK inhibitors bind covalently to cysteine 481 (C481) residues in the BTK active site, c | BTK structure . BTK is composed of four major domains: an N-terminal pleckstrin homology (PH) domain, a TEC homology (TH) domain, two SRC homology domains (SH3 followed by SH2), and a C-terminal kinase domain. d | A list of kinases that contain a C481 residue in the active kinase site. The IC50 is shown for ibrutinib using a purified kinase assay. Younes, A. et al. (2016) The landscape of new drugs in lymphoma Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.205